Treatment with dupilumab for 16 weeks had a marked effect on hand eczema symptoms, including in health-related quality of life (HRQoL).
The current investigation, published in the Journal of the American Academy of Dermatology, was a post-hoc analysis from the LIBERTY-AD-HAFT trial.
First author, Eric Simpson, MD, MCR, is professor of dermatology with Oregon Health & Science University. The authors were not available for interview, but we have distilled and organized excerpts from the paper into a Q&A format to make it useful for readers.
What was the impetus for this post-hoc analysis?
Chronic hand eczema interferes with daily activities and is associated with high disease burden leading to psychosocial stress, decreased work productivity, and increased healthcare costs. HRQoL is an important factor to guide the therapeutic approach.
